BAX and breast cancer: Results indicate that miRNA-128 (miR-128) is more highly expressed in drug-resistant breast cancer samples compared to drug-sensitive samples, and the decrease of miRNA-128 enhances the sensibility of breast cancer cells to chemodrugs by targeting B cell lymphoma 2-associated X (Bax) [21].